Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BMS 986416

Next Previous
Drug Profile

BMS 986416

Alternative Names: AVID-200; AVID200 DP; BMS-986416; TGFβ inhibitor - Bristol Myers Squibb

Latest Information Update: 28 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Formation Biologics
  • Developer Bristol-Myers Squibb
  • Class Antifibrotics; Antineoplastics; Immunoglobulin fusion proteins; Immunotherapies; Skin disorder therapies
  • Mechanism of Action Transforming growth factor beta1 inhibitors; Transforming growth factor beta3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • No development reported Diffuse scleroderma; Myelofibrosis

Most Recent Events

  • 09 Apr 2025 Development for phase I trial in Solid-tumours(Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Japan, USA and Canada is still ongoing (Parenteral) (NCT04943900)
  • 09 Apr 2025 Development for phase I trial in Solid-tumours(Monotherapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Japan, USA and Canada is still ongoing (Parenteral) (NCT04943900)
  • 27 Feb 2025 Bristol-Myers Squibb completes the phase I trial in Solid tumours (Combination therapy, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater, Late-stage disease) in Argentina, Belgium, Canada, Chile, Japan, Netherlands and USA (Parenteral) (NCT04943900)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top